ZLAB
Companies
NASDAQ
Zai Lab Ltd.
Health Care
$36.91
+$10.72 (+40.93%)
Price Chart
Overview
About ZLAB
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.
Market Cap
$2.0B
Volume
36.3M
Avg. Volume
49.0M
P/E Ratio
-17.08377
Dividend Yield
0.00%
Employees
1.2K
Company Information
Risk & Correlation Analysis
Market Correlation
1.25
Moderate Correlation
Volatility
High (0.59)
Relative to market
Macro Factor Sensitivities
Interest Rates
Medium Sensitivity
Inflation
High Sensitivity
GDP Growth
Medium Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
Medium Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, ZLAB shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$2.0B
Volume36.3M
P/E Ratio-17.08
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 8, 2025Related Securities
Pricing info last updated June 17, 2025 (after market close)Other info last updated April 2, 2025